Placental-Cadherin, a Biomarker for Local Immune Status and Poor Prognosis Among Patients with Tongue Squamous Cell Carcinoma

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2021 Nov 26

PMID 34825969

Citations 4

Authors

Haixia Wang

Tianliang Yu

Limin Mao

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic and clinicopathological value of placental-Cadherin (CDH3) in multiple cancers is controversial. The diagnostic significance and functional mechanism of CDH3 in tongue squamous cell carcinoma (TSCC) have not been thoroughly investigated. This study aims to clarify the potential of CDH3 as biomarker for TSCC.

Methods: Here, meta-analysis, bioinformatics, along wet-lab techniques were employed to evaluate the diagnostic, as well as the prognostic value of CDH3 in diverse types of cancers, especially TSCC. Meta-analysis was used to determine the influence of CDH3 on prognostic and clinicopathological features in numerous cancers. Molecular biology function was used to investigate the role of CDH3 in TSCC cells. The relationship of CDH3 with tumor-infiltrating immune cells (TIICs) in TSCC was assessed using CIBERSORT. Moreover, gene set enrichment analysis (GSEA) was done based on TCGA. Besides, the hub genes and associated cascades were uncovered based on gene co-expression with CDH3.

Results: CDH3 upregulation correlated with worse overall survival and disease-free survival in various cancers. CDH3 was validated as an independent risk factor for HNSC and was linked to the onset of tumors, tumor stage, and infiltration depth. CDH3 silencing inhibited cell growth and induced apoptosis of the CAL-27 cell line. CDH3 expression level correlated with infiltration by macrophages, T cells, T cell regulatory cells (Tregs), and plasma cells in TSCC. GSEA revealed that CDH3 influences multiple cancer-associated cascades. Besides, CBX3, CCHCR1, along NFYC were identified as the core hub genes for CDH3.

Conclusion: We identified CDH3 as a pan-cancer gene with potential prognostic and diagnostic significance in various cancers, particularly in TSCC, where it is tumorigenic.

Citing Articles

CDH3 Is an Effective Serum Biomarker of Colorectal Cancer Distant Metastasis Patients.

Song J, Jin Y, Fan S, Wei Y, Dong D, Jia L J Cancer. 2024; 15(16):5218-5229.

PMID: 39247592 PMC: 11375550. DOI: 10.7150/jca.98337.

Machine learning-based prediction of candidate gene biomarkers correlated with immune infiltration in patients with idiopathic pulmonary fibrosis.

Zhang Y, Wang C, Xia Q, Jiang W, Zhang H, Amiri-Ardekani E Front Med (Lausanne). 2023; 10:1001813.

PMID: 36860337 PMC: 9968813. DOI: 10.3389/fmed.2023.1001813.

An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer.

Samadi P, Soleimani M, Nouri F, Rahbarizadeh F, Najafi R, Jalali A BMC Cancer. 2022; 22(1):835.

PMID: 35907803 PMC: 9339198. DOI: 10.1186/s12885-022-09931-4.

P-Cadherin Regulates Intestinal Epithelial Cell Migration and Mucosal Repair, but Is Dispensable for Colitis Associated Colon Cancer.

Naydenov N, Lechuga S, Zalavadia A, Mukherjee P, Gordon I, Skvasik D Cells. 2022; 11(9).

PMID: 35563773 PMC: 9100778. DOI: 10.3390/cells11091467.

References

Perumal V, Corica T, Dharmarajan A, Sun Z, Dhaliwal S, Dass C . Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives. Cancers (Basel). 2019; 11(3). PMC: 6468366. DOI: 10.3390/cancers11030367. View

Zhou H, Zhang J, Guo L, Nie J, Zhu C, Ma X . The value of narrow band imaging in diagnosis of head and neck cancer: a meta-analysis. Sci Rep. 2018; 8(1):515. PMC: 5765024. DOI: 10.1038/s41598-017-19069-0. View

Jansen L, Buttmann-Schweiger N, Listl S, Ressing M, Holleczek B, Katalinic A . Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site. Oral Oncol. 2018; 76:8-15. DOI: 10.1016/j.oraloncology.2017.11.015. View

Zhu P, He L, Li Y, Huang W, Xi F, Lin L . OTG-snpcaller: an optimized pipeline based on TMAP and GATK for SNP calling from ion torrent data. PLoS One. 2014; 9(5):e97507. PMC: 4019570. DOI: 10.1371/journal.pone.0097507. View

Gardner S, Frey K, Redden C, Thissen J, Allen J, Allred A . Targeted amplification for enhanced detection of biothreat agents by next-generation sequencing. BMC Res Notes. 2015; 8:682. PMC: 4647626. DOI: 10.1186/s13104-015-1530-0. View

Hulpiau P, van Roy F . Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2008; 41(2):349-69. DOI: 10.1016/j.biocel.2008.09.027. View

Sasaki M, Akiyama-Oda Y, Oda H . Evolutionary origin of type IV classical cadherins in arthropods. BMC Evol Biol. 2017; 17(1):142. PMC: 5473995. DOI: 10.1186/s12862-017-0991-2. View

Cappellesso R, Marioni G, Crescenzi M, Giacomelli L, Guzzardo V, Mussato A . The prognostic role of the epithelial-mesenchymal transition markers E-cadherin and Slug in laryngeal squamous cell carcinoma. Histopathology. 2015; 67(4):491-500. DOI: 10.1111/his.12668. View

Schreyer L, Mittermeier C, Franz M, Meier M, Martin D, Maier K . Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence. Cancers (Basel). 2021; 13(21). PMC: 8582588. DOI: 10.3390/cancers13215373. View

10.

Kourtidis A, Lu R, Pence L, Anastasiadis P . A central role for cadherin signaling in cancer. Exp Cell Res. 2017; 358(1):78-85. PMC: 5544584. DOI: 10.1016/j.yexcr.2017.04.006. View

11.

Nose A, Takeichi M . A novel cadherin cell adhesion molecule: its expression patterns associated with implantation and organogenesis of mouse embryos. J Cell Biol. 1986; 103(6 Pt 2):2649-58. PMC: 2114609. DOI: 10.1083/jcb.103.6.2649. View

12.

Vieira A, Paredes J . P-cadherin and the journey to cancer metastasis. Mol Cancer. 2015; 14:178. PMC: 4595126. DOI: 10.1186/s12943-015-0448-4. View

13.

Shimoyama Y, Hirohashi S . Expression of E- and P-cadherin in gastric carcinomas. Cancer Res. 1991; 51(8):2185-92. View

14.

Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H . Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005; 65(8):3092-9. DOI: 10.1158/0008.5472.CAN-04-3646. View

15.

Bauer R, Valletta D, Bauer K, Thasler W, Hartmann A, Muller M . Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumorigenicity. Int J Clin Exp Pathol. 2014; 7(9):6125-32. PMC: 4203231. View

16.

Smythe W, Williams J, Wheelock M, Johnson K, Kaiser L, Albelda S . Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. Lung Cancer. 1999; 24(3):157-68. DOI: 10.1016/s0169-5002(99)00032-x. View

17.

Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y . P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res. 2005; 65(19):8774-83. DOI: 10.1158/0008-5472.CAN-04-4414. View

18.

Li L, Yu S, Wu Q, Dou N, Li Y, Gao Y . KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3β Signaling. Int J Biol Sci. 2019; 15(5):953-961. PMC: 6535787. DOI: 10.7150/ijbs.30857. View

19.

Al Absi A, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X . Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity. Cancer Res. 2018; 78(19):5631-5643. DOI: 10.1158/0008-5472.CAN-18-0441. View

20.

Insua-Rodriguez J, Oskarsson T . The extracellular matrix in breast cancer. Adv Drug Deliv Rev. 2016; 97:41-55. DOI: 10.1016/j.addr.2015.12.017. View